A randomized, placebo-controlled proof-of-concept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder


    loading  Checking for direct PDF access through Ovid

Abstract

Background and Objectives:Topiramate is effective for alcohol use disorders (AUDs) among non-psychiatric patients. We examined topiramate for treating comorbid AUDs in bipolar disorder (BD).Methods:Twelve participants were randomized to topiramate or placebo for 12 weeks.Results:The topiramate group, with two out of five participants (40%) completing treatment, experienced less improvement in drinking patterns than the placebo group, with five out of seven participants (71%) completing treatment.Discussion and Conclusions:Topiramate did not improve drinking behavior and was not well-tolerated. This study failed to recruit adequately. Problems surrounding high attrition, a small study sample, and missing data preclude interpretation of study findings.Scientific Significance:This is the first randomized, placebo-controlled trial of topiramate for AUDs in BD. (Am J Addict 2016;25:94–98)

    loading  Loading Related Articles